Innate Pharma S.A. is a clinical-stage biotechnology company specializing in immuno-oncology and dedicated to improving the treatment of cancers using innovative therapeutic antibodies acting on the immune system.
Innate Pharma's broad antibody portfolio includes several potentially first-in-class candidates at clinical and preclinical stages in cancers where the medical need is high.
Innate Pharma is a pioneer in understanding NK cell biology and has developed expertise in the tumor microenvironment and tumor antigens, as well as antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and establish alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi as well as a multi-product partnership with AstraZeneca.
Innate Pharma is listed on the Euronext Paris and Nasdaq stock exchanges.